Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DENALI-1: A2B395 in Advanced Solid Tumors
NCT06682793Phase 2Recruiting
- Sponsor
- A2 Biotherapeutics
- Start
- May 2025
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of A2B395 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 2 more, sponsored by A2 Biotherapeutics. Primary endpoints: Rate of adverse events and dose limiting toxicities at 24 months, Recommended Phase 2 Dose at 28 days and 1 more. Started May 2025; status: recruiting.
02
Drugs
A2B395
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06682793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682793.